Session » RA – Diagnosis, Manifestations, & Outcomes Poster III: Cardiopulmonary Aspects

Date: Sunday, November 8, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1196

Associations of Biological Sex with Interstitial Lung Disease in Patients with Rheumatoid Arthritis Are Independent of Other Known Risk Factors

9:00AM-11:00AM: Abstract Number: 1178

Associations of Walking Endurance and Speed with Multiple Measures of Subclinical Cardiovascular Disease in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1197

Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1179

Cardiovascular Risk Assessment with Carotid Ultrasonography in Addition to the Traditional Cardiovascular Risk Factor in Rheumatoid Arthritis: A Case Control Study

9:00AM-11:00AM: Abstract Number: 1180

External Validation of a Multi-biomarker-Based Cardiovascular Disease Risk Prediction Score for Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1183

Factors Associated with Incident Heart Failure Subtypes in Patients with Rheumatoid Arthritis Using Electronic Health Record Data

9:00AM-11:00AM: Abstract Number: 1181

Gains in Cardiovascular Risk Knowledge Through Web Based Educational Intervention for Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1184

In a Prospective RA Cohort, Higher Baseline Disease Activity Is an Independent Predictor of Decline in Left Ventricular Diastolic Function

9:00AM-11:00AM: Abstract Number: 1182

Increased Prevalence of Carotid Atherosclerosis in Postmenopausal Women with Rheumatoid Arthritis: A Case Control Study

9:00AM-11:00AM: Abstract Number: 1198

Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1194

MUC5B Promoter Variant rs35705950 and Risk Stratification for Rheumatoid Arthritis – Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1195

MUC5B rs35705950 and Rheumatoid Arthritis Associated Interstitial Lung Disease Progression

9:00AM-11:00AM: Abstract Number: 1185

Performance of the MBDA-based CVD Risk Score in RA Patient Groups of Clinical Interest

9:00AM-11:00AM: Abstract Number: 1199

Prevalence of Subclinical Interstitial Lung Disease After a Mean Rheumatoid Arthritis Duration of 13 Years: Results from the French ESPOIR Cohort

9:00AM-11:00AM: Abstract Number: 1186

Red Cell Distribution Width and Absolute Lymphocyte Count Associate with Biomarkers of Inflammation and Subsequent Mortality in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1187

Red Cell Distribution Width Is Associated with ASCVD Risk Score and CVD in RA After Initiation of Methotrexate

9:00AM-11:00AM: Abstract Number: 1188

Serum Anti-malondialdehyde-acetaldehyde IgA Antibody Concentration Improves Prediction of Coronary Atherosclerosis Beyond Traditional Risk Factors in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1200

Serum Anti-PAD4 and Anti-PAD3/4XR Antibodies in Rheumatoid Arthritis Associated-Interstitial Lung Disease Are Associated with Better Lung Function

9:00AM-11:00AM: Abstract Number: 1189

Serum High-sensitive Cardiac Troponin at Baseline Predict Cardiovascular Events in Rheumatoid Arthritis and Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1190

Sex Differences in Cardiovascular Disease Prevention in Patients with Rheumatoid Arthritis: World-wide Data from the SURF-RA

9:00AM-11:00AM: Abstract Number: 1191

Specificity for Inflammatory Pathways Associated with Coronary Microvascular Dysfunction in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1192

Subclinical Coronary Calcification Associated with Long-term Cardiovascular Outcomes in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1193

Unsupervised Molecular Profile Clustering in the Serum of Rheumatoid Arthritis Patients Identifies Groups with Differential CV-risk SCORE: Modulation by Biological Therapies

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].